Grufity logoGrufity logo

CRSP

54.99USD-0.04(-0.07%)Market Closed

CRISPR Therapeutics AG

Market Summary

USD54.99-0.04Market Closed
-0.07%

CRSP Alerts

CRSP Stock Price

RSI Chart

Valuation

Market Cap

4.2B

Price/Earnings

-6.69

Price/Sales

4.37

Price/Cashflow

-9.53

MarketCap/EBT

-6.76

Price/Sales

Profitability

EBT Margin

-68.48%

Return on Equity

-30.3%

Return on Assets

-25.71%

Fundamentals

Revenue

Revenue Y/Y

-99.98%

Revenue Q/Q

-40.51%

Earnings

Earnings (TTM)

-680.8M

Earnings Y/Y

-37.27%

Earnings Q/Q

6.07%

Price Action

52 Week Range

42.5186.95
(Low)(High)

Last 7 days

-4.8%

Last 30 days

-0.4%

Last 90 days

-18.4%

Trailing 12 Months

-32.0%

Financial Health

Current Ratio

17.57

Investor Care

Shares Dilution (1Y)

2.31%

Diluted EPS (TTM)

-8.7

Peers (Alternatives to CRISPR Therapeutics AG)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
7.14% 43.50%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
21.80% 28.96%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
24.23% -35.48%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
8.82% 22.00%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
7.16% 39.03%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
7.23% -37.09%
-12.87
32.5
-41.50% -607.58%
3.4B
-
-6.88% -45.94%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
-4.89% -63.56%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
-5.28% -44.88%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-27.49% -91.73%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-21.14% -78.94%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
12.62% -35.50%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-18.16% -60.18%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-23.83% -90.20%
-13.56
44.06
522.71% -129.91%
218.9M
-
-24.71% -82.02%
-2.36
609.63
-71.03% -64.56%

Financials for CRISPR Therapeutics AG

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
RevenueNaN%nullnullnull915848
Operating Expenses8.1%701649603541491
  S&GA Expenses2.6%105103106103104
  R&D Expenses2.3%493481466439387
Earnings Before Taxes-7.6%-673.95-626.57317380416
Net Income-7.5%-680.85-633.45312378412
* denotes actual numbers (not divided by Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-4.5%2,3532,4632,6062,7522,822
  Current Assets-8.3%1,9332,1072,2612,4182,519
    Cash Equivalents-0.6%4944976849231,012
  Net PPE0.6%166165157138106
Liabilities7.2%399373361352309
  Current Liabilities25.8%15112011412096
Shareholder's Equity-6.5%1,9542,0912,2452,3992,513
  Retained Earnings-31.1%-735.51-560.97-375.13-195.91-54.67
  Additional Paid-In Capital1.5%2,7092,6702,6352,5982,566
Accumulated Depreciation-45.3%2851443833
Shares Outstanding0.6%7878777776
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-5.4%-468.45-444.56504539544
  Share Based Compensation-1.6%10110310610296
Cashflow From Investing87.7%-91.84-744.48-982.05-1,035.43-1,230.96
Cashflow From Financing13.1%423836251657

Risks

What is the probability of a big loss on CRSP?

100%


Probability that CRISPR Therapeutics AG stock will be more than 20% underwater in next one year

86.9%


Probability that CRISPR Therapeutics AG stock will be more than 30% underwater in next one year.

73.5%


Probability that CRISPR Therapeutics AG stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CRSP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if CRISPR Therapeutics AG was unfortunately bought at previous high price.

Returns

Cumulative Returns on CRSP

22.4%


5-Year Cumulative Returns

-7.2%


3-Year Cumulative Returns

What are the long-term rolling returns for CRSP?

FIve years rolling returns for CRISPR Therapeutics AG.

Which funds bought or sold CRSP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Gould Capital, LLC
UNCHANGED
-
1,000
6,000
-%
2022-11-22
B. Riley Wealth Advisors, Inc.
REDUCED
-5.08
11,000
527,000
0.02%
2022-11-22
IHT Wealth Management, LLC
-
-
208,000
656,000
0.05%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
1,554,000
1,554,000
0.06%
2022-11-21
FourThought Financial, LLC
-
-
1,000
11,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
324,000
4,137,000
0.01%
2022-11-21
Parallax Volatility Advisers, L.P.
NEW
-
472,000
472,000
-%
2022-11-16
GLENMEDE TRUST CO NA
NEW
-
379,000
379,000
-%
2022-11-16
Front Row Advisors LLC
NEW
-
1,232,000
1,232,000
0.64%
2022-11-16
LIBERTY ONE INVESTMENT MANAGEMENT, LLC
ADDED
133.55
-15,000
256,000
0.04%

1–10 of 43

Latest Funds Activity

Are funds buying CRSP calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own CRSP

CRISPR Therapeutics AG News

InvestorsObserver

Crispr Therapeutics AG (CRSP) Stock: Do Analysts Think You Should Sell?.2 days ago

Banyan Hill Publishing

CRSP Fair Value

Recent SEC filings of CRISPR Therapeutics AG

View All Filings
Date Filed Form Type Document
Nov 01, 2022
10-Q
Quarterly Report
Nov 01, 2022
8-K
Current Report
Oct 28, 2022
4
Insider Trading
Oct 27, 2022
8-K
Current Report
Oct 18, 2022
4
Insider Trading
Oct 12, 2022
4
Insider Trading
Oct 12, 2022
4
Insider Trading
Oct 12, 2022
4
Insider Trading
Sep 27, 2022
8-K
Current Report
Aug 31, 2022
4
Insider Trading

Latest Insider Trading transactions for CRSP

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-26
Kulkarni Samarth
ACQUIRED
421,016
16.8407
25,000
Chief Executive Officer
2022-10-26
Kulkarni Samarth
SOLD
-1,370,190
54.8076
-25,000
Chief Executive Officer
2022-10-17
Smith Brendan
SOLD FOR TAXES
-61,949.4
55.76
-1,111
Chief Financial Officer
2022-10-14
Smith Brendan
ACQUIRED
-
-
3,750
Chief Financial Officer
2022-08-29
Kulkarni Samarth
ACQUIRED
405,250
16.21
25,000
Chief Executive Officer
2022-08-29
Kulkarni Samarth
SOLD
-1,671,080
66.8434
-25,000
Chief Executive Officer
2022-07-27
Kulkarni Samarth
SOLD
-1,897,750
75.9099
-25,000
Chief Executive Officer
2022-07-27
Kulkarni Samarth
ACQUIRED
374,918
14.9967
25,000
Chief Executive Officer
2022-06-29
Kulkarni Samarth
ACQUIRED
314,250
12.57
25,000
Chief Executive Officer
2022-06-29
Kulkarni Samarth
SOLD
-1,539,860
61.5945
-25,000
Chief Executive Officer

1–10 of 50

Samarth Kulkarni
470
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRSP Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Total revenue$ 94$ 824$ 1,192$ 902,064
Operating expenses:    
Research and development116,62283,500358,090237,472
General and administrative27,00123,70981,29576,012
Collaboration expense, net38,85922,464103,42769,354
Total operating expenses182,482129,673542,812382,838
(Loss) income from operations(182,388)(128,849)(541,620)519,226
Other income:    
Other income, net7,2641,10111,1713,806
Total other income, net7,2641,10111,1713,806
Net (loss) income before income taxes(175,124)(127,748)(530,449)523,032
Benefit (provision) for income taxes575595(9,151)(4,123)
Net (loss) income(174,549)(127,153)(539,600)518,909
Foreign currency translation adjustment(100)(24)(195)(14)
Unrealized loss on marketable securities(1,820)(117)(17,001)(673)
Comprehensive (loss) income$ (176,469)$ (127,294)$ (556,796)$ 518,222
Net (loss) income per common share - basic$ (2.24)$ (1.67)$ (6.96)$ 6.85
Basic weighted-average common shares outstanding78,021,52076,288,53477,547,77175,712,437
Net (loss) income per common share - diluted$ (2.24)$ (1.67)$ (6.96)$ 6.44
Diluted weighted-average common shares outstanding78,021,52076,288,53477,547,77180,554,682
Collaboration Revenue [Member]    
Revenue:    
Total revenue$ 94$ 329$ 430$ 900,733
Grant Revenue [Member]    
Revenue:    
Total revenue$ 0$ 495$ 762$ 1,331

CRSP Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 494,151$ 923,031
Marketable securities1,401,8241,456,098
Accounts receivable49305
Prepaid expenses and other current assets36,67938,079
Total current assets1,932,7032,417,513
Property and equipment, net166,110137,575
Marketable securities, non-current77,1470
Intangible assets, net84125
Restricted cash12,12316,913
Operating lease assets161,507174,460
Other non-current assets3,6825,291
Total assets2,353,3562,751,877
Current liabilities:  
Accounts payable32,11414,816
Accrued expenses102,95491,003
Deferred revenue, current 1,011
Accrued tax liabilities4,272724
Operating lease liabilities11,26012,158
Other current liabilities270171
Total current liabilities150,870119,883
Deferred revenue, non-current12,32312,323
Operating lease liabilities, net of current portion230,895212,872
Other non-current liabilities5,3147,339
Total liabilities399,402352,417
Commitments and contingencies, see Note 6
Shareholders’ equity:  
Common shares, CHF 0.03 par value, 150,347,467 and 145,364,335 shares authorized at September 30, 2022 and December 31, 2021, respectively, 78,428,146 and 77,170,382 shares issued at September 30, 2022 and December 31, 2021, respectively, 78,247,830 and 76,990,066 shares outstanding at September 30, 2022 and December 31, 2021, respectively2,4332,391
Treasury shares, at cost, 180,316 shares at September 30, 2022 and at December 31, 2021(63)(63)
Additional paid-in capital2,709,3612,598,114
Accumulated deficit(735,515)(195,915)
Accumulated other comprehensive loss(22,262)(5,067)
Total shareholders' equity1,953,9542,399,460
Total liabilities and shareholders’ equity$ 2,353,356$ 2,751,877